Successfully tackling a Norovirus outbreak
Norovirus is associated with outbreaks of diarrhoea and vomiting which are usually not clinically significant. However, Norovirus outbreaks can cause significant financial and operational difficulties to a hospital.
The virus is extremely contagious and necessitates patient isolation and regular ward closure. Although clinical outcomes are not typically severe, Norovirus affects both patients and healthcare workers (HCWs).
Bed blocking caused by the virus restricts the ability of hospitals to generate revenue through additional admissions. Further, there are often substantial ‘catch-up’ costs relating to cancelled procedures.
Bioquell’s Norovirus Suppression Programme is designed to eliminate rapidly Norovirus from contaminated patient areas, reducing the risk of transmission and facilitating more efficient cohorting. Each plan is tailored to individual hospital requirements and allows hospitals to maximise the benefit of Bioquell’s technology and ensure full integration with any existing infection control bundles.
Our bespoke programme reduces the spread of Norovirus and helps generate significant cost-benefits.
Bioquell has developed the Norovirus Suppression Programme to overcome issues associated with the speed of Norovirus onset, the scale of environmental contamination and the operational issues it causes. Hospitals can combine their own preferred protocols and infection control bundles with Bioquell’s knowledge of contamination risk-management and control, alongside our best practice lessons learnt during ‘real world’ Norovirus deployments.
Bioquell’s Norovirus Suppression Programme is agreed in detail with the hospital in preparation for the onset of an outbreak and typically includes:
Bioquell’s Norovirus Suppression Programme comprises a strategy based on best practice, which can be tailored to the specific requirements of the hospital. In effect, the plan is a pre-designed, pre-planned reactive service. It involves Bioquell engineers and equipment deploying rapidly to a hospital site at the onset of the outbreak, sometimes with equipment pre-located at the hospital. They then remain there to limit the spread of Norovirus by performing room or unit bio-decontaminations until the Norovirus outbreak has been arrested.
During the peak of a Norovirus outbreak, the Bioquell deployment will run in a very similar manner to Bioquell’s Proactive service, with personnel integrated within the hospital undertaking the Norovirus response on a daily basis. By reducing the extent of outbreaks and allowing more efficient cohorting, the Bioquell Norovirus suppression plan can help minimise unit closures, allowing hospitals to improve patient throughput and bed availability during the busy winter months. Hospitals can then achieve significant cost benefit by admitting additional patients to increase revenue generation. Further costs will also be saved by reducing the requirement for temporary replacement staff as Norovirus outbreaks are contained.
|
“We feel that using Bioquell has helped reduce the spread of Norovirus in our hospital over the last two years, and now forms a critical part of our Norovirus remediation procedures.” Ann Kerrane, Matron for infection prevention and control, The Rotherham NHS Foundation Trust. |
What is your evidence that using Bioquell will reduce Norovirus?
Norovirus transmission is known to have a large environmental component, as it survives in the environment for a long time and has an extremely low infective dose. There is anecdotal evidence from hospitals that using Bioquell has helped reduce the spread of Norovirus, though no research has yet been published. Bioquell is interested in collaborating with a hospital on such research.
Bioquell RBDS provides a safe, reliable bio-decontamination solution to help heathcare professionals tackle hospital aquired infections (HAI/HCAI) and stop outbreaks of drug resistant pathogens.
Bioquell RBDS provides a safe, reliable bio-decontamination solution to help heathcare professionals tackle hospital aquired infections (HAI/HCAI) and stop outbreaks of drug resistant pathogens.